157 related articles for article (PubMed ID: 33638656)
1. PBK expression predicts favorable survival in colorectal cancer patients.
Nagano-Matsuo A; Inoue S; Koshino A; Ota A; Nakao K; Komura M; Kato H; Naiki-Ito A; Watanabe K; Nagayasu Y; Hosokawa Y; Takiguchi S; Kasugai K; Kasai K; Inaguma S; Takahashi S
Virchows Arch; 2021 Aug; 479(2):277-284. PubMed ID: 33638656
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic, nuclear, and total PBK/TOPK expression is associated with prognosis in colorectal cancer patients: A retrospective analysis based on immunohistochemistry stain of tissue microarrays.
Su TC; Chen CY; Tsai WC; Hsu HT; Yen HH; Sung WW; Chen CJ
PLoS One; 2018; 13(10):e0204866. PubMed ID: 30286126
[TBL] [Abstract][Full Text] [Related]
3. PBK promotes aggressive phenotypes of cervical cancer through ERK/c-Myc signaling pathway.
Ma H; Han F; Yan X; Qi G; Li Y; Li R; Yan S; Yuan C; Song K; Kong B
J Cell Physiol; 2021 Apr; 236(4):2767-2781. PubMed ID: 33184870
[TBL] [Abstract][Full Text] [Related]
4. PBK Enhances Cellular Proliferation With Histone H3 Phosphorylation and Suppresses Migration and Invasion With CDH1 Stabilization in Colorectal Cancer.
Koshino A; Nagano A; Ota A; Hyodo T; Ueki A; Komura M; Sugimura-Nagata A; Ebi M; Ogasawara N; Kasai K; Hosokawa Y; Kasugai K; Takahashi S; Inaguma S
Front Pharmacol; 2021; 12():772926. PubMed ID: 35115926
[TBL] [Abstract][Full Text] [Related]
5. BZW2 promotes the malignant progression of colorectal cancer via activating the ERK/MAPK pathway.
Huang L; Chen S; Fan H; Ai F; Sheng W
J Cell Physiol; 2020 May; 235(5):4834-4842. PubMed ID: 31643092
[TBL] [Abstract][Full Text] [Related]
6. miR-216b promotes cell growth and enhances chemosensitivity of colorectal cancer by suppressing PDZ-binding kinase.
Zou J; Kuang W; Hu J; Rao H
Biochem Biophys Res Commun; 2017 Jun; 488(2):247-252. PubMed ID: 28373071
[TBL] [Abstract][Full Text] [Related]
7. PBK/TOPK Expression Predicts Prognosis in Oral Cancer.
Chang CF; Chen SL; Sung WW; Hsieh MJ; Hsu HT; Chen LH; Chen MK; Ko JL; Chen CJ; Chou MC
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347940
[TBL] [Abstract][Full Text] [Related]
8. PDZ-binding kinase inhibitor OTS514 suppresses the proliferation of oral squamous carcinoma cells.
Kato M; Ota A; Ono T; Karnan S; Hyodo T; Rahman ML; Hasan MN; Onda M; Kondo S; Ito K; Furuhashi A; Hayashi T; Konishi H; Tsuzuki S; Hosokawa Y; Kazaoka Y
Oral Dis; 2024 Mar; 30(2):223-234. PubMed ID: 36799330
[TBL] [Abstract][Full Text] [Related]
9. Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis.
Gao T; Hu Q; Hu X; Lei Q; Feng Z; Yu X; Peng C; Song X; He H; Xu Y; Zuo W; Zeng J; Liu Z; Yu L
Cancer Lett; 2019 Mar; 445():11-23. PubMed ID: 30590102
[TBL] [Abstract][Full Text] [Related]
10. PBK Expression Is Associated With Prognosis of Patients With Oral Squamous Cell Carcinoma Treated With Radiotherapy: A Retrospective Study.
Yu WN; Lin HF; Lee YI; Shia WC; Sung WW; Yeh CM; Lin YM
Anticancer Res; 2021 Apr; 41(4):2177-2182. PubMed ID: 33813430
[TBL] [Abstract][Full Text] [Related]
11. Baicalin suppresses lung cancer growth by targeting PDZ-binding kinase/T-LAK cell-originated protein kinase.
Diao X; Yang D; Chen Y; Liu W
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30898980
[TBL] [Abstract][Full Text] [Related]
12. Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.
Stefka AT; Johnson D; Rosebeck S; Park JH; Nakamura Y; Jakubowiak AJ
Cancer Med; 2020 Jan; 9(1):324-334. PubMed ID: 31714026
[TBL] [Abstract][Full Text] [Related]
13. Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase.
Wang L; Zhang Z; Ge R; Zhang J; Liu W; Mou K; Lv S; Mu X
Anticancer Agents Med Chem; 2019; 19(8):1029-1036. PubMed ID: 30827262
[TBL] [Abstract][Full Text] [Related]
14. Novel Interleukin-6 Inducible Gene PDZ-Binding Kinase Promotes Tumor Growth of Multiple Myeloma Cells.
Ota A; Hanamura I; Karnan S; Inaguma S; Takei N; Lam VQ; Mizuno S; Kanasugi J; Wahiduzzaman M; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Ikeda H; Takami A; Hosokawa Y
J Interferon Cytokine Res; 2020 Aug; 40(8):389-405. PubMed ID: 32721246
[TBL] [Abstract][Full Text] [Related]
15. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC.
Kar A; Zhang Y; Yacob BW; Saeed J; Tompkins KD; Bagby SM; Pitts TM; Somerset H; Leong S; Wierman ME; Kiseljak-Vassiliades K
Endocr Relat Cancer; 2019 Oct; 26(10):765-778. PubMed ID: 31325906
[TBL] [Abstract][Full Text] [Related]
16. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo.
Joel M; Mughal AA; Grieg Z; Murrell W; Palmero S; Mikkelsen B; Fjerdingstad HB; Sandberg CJ; Behnan J; Glover JC; Langmoen IA; Stangeland B
Mol Cancer; 2015 Jun; 14():121. PubMed ID: 26081429
[TBL] [Abstract][Full Text] [Related]
17. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
[TBL] [Abstract][Full Text] [Related]
18. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
[TBL] [Abstract][Full Text] [Related]
19. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
20. PBK/TOPK expression correlates with mutant p53 and affects patients' prognosis and cell proliferation and viability in lung adenocarcinoma.
Lei B; Qi W; Zhao Y; Li Y; Liu S; Xu X; Zhi C; Wan L; Shen H
Hum Pathol; 2015 Feb; 46(2):217-24. PubMed ID: 25466965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
